Iovance Biotherapeutics, Inc. (IOVA) Stock Forecast
Data as of Oct 31, 2026Healthcare · Current price $8.36 (-12.60%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 5, 2026 | Andrea Newkirk | Goldman Sachs | $2.00 | -76.1% |
| May 16, 2025 | David Dai | UBS | $2.00 | -76.1% |
| Jan 31, 2025 | Joseph Catanzaro | Piper Sandler | $7.50 | -10.2% |
| Oct 24, 2024 | David Dai | UBS | $17.00 | +103.5% |
| Aug 9, 2024 | Benjamin Burnett | Stifel Nicolaus | $11.50 | +37.6% |
| Aug 9, 2024 | Colleen Kusy | Robert W. Baird | $12.00 | +43.6% |
| Jul 29, 2024 | Joseph Catanzaro | Piper Sandler | $10.00 | +19.7% |
| Jun 20, 2024 | Reni Benjamin | JMP Securities | $11.50 | +37.6% |
| May 31, 2024 | Benjamin Burnett | Stifel Nicolaus | $14.00 | +67.6% |
| Mar 14, 2024 | Joseph Catanzaro | Piper Sandler | $19.00 | +127.4% |
| Dec 8, 2022 | Madhu Kumar | Goldman Sachs | $6.00 | -28.2% |
| Nov 20, 2022 | Joseph Catanzaro | Piper Sandler | $11.00 | +31.7% |
| Aug 23, 2022 | Michael Ulz | Robert W. Baird | $12.50 | +49.6% |
| Apr 7, 2022 | Colleen Kusy | Robert W. Baird | $34.00 | +306.9% |
| Apr 5, 2022 | Colleen M. Kusy | Robert W. Baird | $30.00 | +259.1% |
| Jan 28, 2022 | Benjamin Burnett | Stifel Nicolaus | $25.00 | +199.2% |
| Jan 5, 2022 | Nick Abbott | Wells Fargo | $25.00 | +199.2% |
| May 19, 2021 | Peter Lawson | Barclays | $40.00 | +378.8% |
Top Analysts Covering IOVA
IOVA vs Sector & Market
| Metric | IOVA | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.18 | 2.25 | 2.41 |
| Analyst Count | 11 | 8 | 19 |
| Target Upside | +60.9% | +153002.0% | +21.5% |
| P/E Ratio | -3.52 | 3.47 | 38.49 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $90M | $107M | $115M | 2 |
| 2027-03-31 | $109M | $130M | $140M | 2 |
| 2027-06-30 | $116M | $138M | $149M | 2 |
| 2027-09-30 | $123M | $147M | $158M | 2 |
| 2027-12-31 | $130M | $155M | $167M | 2 |
| 2028-12-31 | $697M | $717M | $737M | 6 |
| 2029-12-31 | $735M | $888M | $1.03B | 5 |
| 2030-12-31 | $866M | $1.05B | $1.22B | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-0.12 | $-0.11 | $-0.09 | 1 |
| 2027-03-31 | $-0.08 | $-0.08 | $-0.06 | 1 |
| 2027-06-30 | $-0.07 | $-0.06 | $-0.05 | 1 |
| 2027-09-30 | $-0.04 | $-0.03 | $-0.03 | 1 |
| 2027-12-31 | $-0.01 | $-0.01 | $-0.01 | 1 |
| 2028-12-31 | $-0.11 | $-0.01 | $0.09 | 6 |
| 2029-12-31 | $0.06 | $0.08 | $0.10 | 4 |
| 2030-12-31 | $0.14 | $0.18 | $0.22 | 2 |
Frequently Asked Questions
What is the analyst consensus for IOVA?
The consensus among 11 analysts covering Iovance Biotherapeutics, Inc. (IOVA) is Buy with an average price target of $13.11.
What is the highest price target for IOVA?
The highest price target for IOVA is $40.00, set by Peter Lawson at Barclays on 2021-05-19.
What is the lowest price target for IOVA?
The lowest price target for IOVA is $2.00, set by David Dai at UBS on 2025-05-16.
How many analysts cover IOVA?
11 analysts have issued ratings for Iovance Biotherapeutics, Inc. in the past 12 months.
Is IOVA a buy or sell right now?
Based on 11 analyst ratings, IOVA has a consensus rating of Buy (2.18/5) with a +60.9% upside to the consensus target of $13.11.
What are the earnings estimates for IOVA?
Analysts estimate IOVA will report EPS of $-0.11 for the period ending 2026-12-31, with revenue estimated at $107M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.